Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 417-433

  Dolman, M ^a   Harmsen, Stefan ^a   Pieters, Ebel H E ^a   Sparidans, Rolf W ^b   Lacombe, Marie ^c   Szokol, Bálint ^d   Orfi, László ^d   Kéri, György ^d   Storm, Gert ^a   Hennink, Wim E ^a   Kok, Robbert J ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Kreatech Biotechnology BV   (Netherlands)

^d Vichem Chemie Ltd   (Hungary)

Author keywords

Drug delivery; Fibrosis; Platinum linker; Sunitinib

Indexed keywords

17864; LYSOZYME; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG KIDNEY LEVEL; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; ENZYME INHIBITION; HUMAN; HUMAN CELL; KIDNEY FIBROSIS; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; SINGLE DRUG DOSE; CYTOTOXICITY TEST; DOSE RESPONSE; DRUG EFFECT; IC 50; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; URETER OBSTRUCTION;

ANIMALS; AREA UNDER CURVE; CELL LINE; CELL SURVIVAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FIBROSIS; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; KIDNEY; KIDNEY DISEASES; KIDNEY TUBULES, PROXIMAL; MALE; MICE; MICE, INBRED C57BL; MURAMIDASE; ORGANOPLATINUM COMPOUNDS; PROTEIN-TYROSINE KINASES; PYRROLES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA;

MUS;

EID: 84856626648     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol. 2010;21(11):1819-1834.
2. Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol. 2010;6(11):643-656.
3. Mezzano SA, Droguett MA, Burgos ME, et al. Overexpression of chemokines, fibrogenic cytokines, and myofibroblasts in human membranous nephropathy. Kidney Int. 2000;57(1):147-158.
4. Sean Eardley K, Cockwell P. Macrophages and progressive tubuloint-erstitial disease. Kidney Int. 2005;68(2):437-455.
5. Hewitson TD. Renal tubulointerstitial fibrosis: common but never simple. Am J Physiol Renal Physiol. 2009;296(6):F1239-F1244.
6. Dolman ME, Harmsen S, Storm G, Hennink WE, Kok RJ. Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cells. Adv Drug Deliv Rev. 2010;62(14): 1344-1357.
7. Ripley E. Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease. Am Heart J. 2009;157(6 Suppl):S7-S16.
8. Yu L, Noble NA, Border WA. Therapeutic strategies to halt renal fibrosis. Curr Opin Pharmacol. 2002;2(2):177-181.
9. Kontovinis LF, Papazisis KT, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris AH. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer. 2009;9:82.
10. Sablin MP, Dreyer C, Colichi C, et al. Benefts from pharmacological and pharmacokinetic properties of sunitinib for clinical development. Expert Opin Drug Metab Toxicol. 2010;6(8):1005-1015.
11. Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161(5):1045-1051.
12. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127-132.
13. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004;15(4):255-273.
14. Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford). 2008;47 Suppl 5:v2-v4.
15. Kanellis J, Paizis K, Cox AJ, et al. Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expression. Kidney Int. 2002;61(5):1696-1706.
16. Malmstrom NK, Kallio EA, Rintala JM, et al. Vascular endothelial growth factor in chronic rat allograft nephropathy. Transpl Immunol. 2008;19(2):136-144.
17. Tugues S, Fernandez-Varo G, Munoz-Luque J, et al. Antiangiogenic treatment with sunitinib ameliorates infammatory infltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology. 2007;46(6):1919-1926.
18. Force T, Krause DS, Van Etten RA. Molecular mechanisms of car-diotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7(5): 332-344.
19. Bovelli D, Plataniotis G, Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21 Suppl 5:v277-v282.
20. Di Lorenzo G, Autorino R, Bruni G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a mul-ticenter analysis. Ann Oncol. 2009;20(9):1535-1542.
21. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008;53(5):917-930.
22. Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer. 2008;16(6):557-566.
23. Prakash J, de Borst MH, Lacombe M, et al. Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury. J Am Soc Nephrol. 2008;19(11):2086-2097.
24. Prakash J, de Borst MH, van Loenen-Weemaes AM, et al. Cell-specifc delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis. Pharm Res. 2008;25(10):2427-2439.
25. Prakash J, Sandovici M, Saluja V, et al. Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis. J Pharmacol Exp Ther. 2006;319(1):8-19.
26. Christensen EI, Verroust PJ, Nielsen R. Receptor-mediated endocytosis in renal proximal tubule. Pfugers Arch. 2009;458(6):1039-1048.
27. Temming K, Fretz MM, Kok RJ. Organ- and cell-type specifc delivery of kinase inhibitors: a novel approach in the development of targeted drugs. Curr Mol Pharmacol. 2008;1(1):1-12.
28. Gonzalo T, Beljaars L, van de Bovenkamp M, et al. Local inhibition of liver fibrosis by specifc delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells. J Pharmacol Exp Ther. 2007;321(3):856-865.
29. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol. 2006;2(7):358-364.
30. Liao JJ. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem. 2007;50(3):409-424.
31. Gajiwala KS, Wu JC, Christensen J, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A. 2009;106(5):1542-1547.
32. Harmsen S, Dolman MEM, Nemes Z, et al. Development of a cell-selective and intrinsically active multikinase inhibitor bioconjugate. Bioconjug Chem. 2011;22(4):540-545.
33. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fuoro-2- oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003;46(7):1116-1119.
34. van Gijlswijk R P, Talman EG, Peekel I, et al. Use of horseradish peroxidase- and fuorescein-modifed cisplatin derivatives for simultaneous labeling of nucleic acids and proteins. Clin Chem. 2002;48(8): 1352-1359.
35. Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH. Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods. 1997;208(2):151-158.
36. Rippe A, Rippe C, Sward K, Rippe B. Disproportionally low clearance of macromolecules from the plasma to the peritoneal cavity in a mouse model of peritoneal dialysis. Nephrol Dial Transplant. 2007;22(1):88-95.
37. Sparidans RW, Iusuf D, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(32):4090-4096.
38. Fretz MM, Dolman ME, Lacombe M, et al. Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors. J Control Release. 2008;132(3):200-207.
39. Temming K, Lacombe M, Schaapveld RQ, et al. Rational design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium. Chem Med Chem. 2006;1(11):1200-1203.
40. Dolman ME, van Dorenmalen KM, Pieters EH, et al. Imatinib-ULS-lysozyme: A proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases. J Control Release. 2011. [Epub ahead of print.] doi:10.1016/j.jconrel.2011.08.041.
41. Huls M, Brown CD, Windass AS, et al. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int. 2008;73(2):220-225.
42. Shukla S, Robey RW, Bates SE, Ambudkar S V. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2009;37(2):359-365.
43. Yang H-C, Zuo Y, Fogo AB. Models of chronic kidney disease. Drug Discov Today Dis Models. 2010;7(1-2):13-19.
44. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329-1338.
45. Chung AC, Huang XR, Zhou L, Heuchel R, Lai KN, Lan HY. Disruption of the Smad7 gene promotes renal fibrosis and infammation in unilateral ureteral obstruction (UUO) in mice. Nephrol Dial Transplant. 2009;24(5):1443-1454.
46. Yuan X P, He XS, Wang CX, Liu LS, Fu Q. Triptolide attenuates renal interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrology (Carlton). 2011;16(2):200-210.
47. Puri TS, Shakaib MI, Chang A, et al. Chronic kidney disease induced in mice by reversible unilateral ureteral obstruction is dependent on genetic background. Am J Physiol Renal Physiol. 2010;298(4): F1024-F1032.
48. Tapmeier TT, Brown KL, Tang Z, Sacks SH, Sheerin NS, Wong W. Reimplantation of the ureter after unilateral ureteral obstruction provides a model that allows functional evaluation. Kidney Int. 2008;73(7): 885-889.
49. Li L, Emmett N, Mann D, Zhao X. Fenofbrate attenuates tubuloint-erstitial fibrosis and infammation through suppression of nuclear factor-kappaB and transforming growth factor-beta1/Smad3 in diabetic nephropathy. Exp Biol Med (Maywood). 2010;235(3):383-391.